Ofloxacin resistance in mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype

Microbial Drug Resistance

Volumn 20, Issue 6, 2014, Pages 525-532

  Sun, Zhaogang ^a   Xu, Yuhui ^a   Sun, Yong ^a   Liu, Yi ^a   Zhang, Xuxia ^a   Huang, Hairong ^a   Li, Chuanyou ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; OFLOXACIN; RESERPINE; RIFAMPICIN; STREPTOMYCIN; VERAPAMIL; BACTERIAL PROTEIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST; PROCEDURES;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; GENOTYPE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84915763601     PISSN: 10766294     EISSN: 19318448     Source Type: Journal    
DOI: 10.1089/mdr.2013.0171     Document Type: Article

References (35)

1. Amaral, L., M. Martins, and M. Viveiros. 2007. Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J. Antimicrob. Chemother. 59:1237-1246.
2. Banerjee, S.K., K. Bhatt, S. Rana, P. Misra, and P.K. Chakraborti. 1996. Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis. Biochem. Biophys. Res. Commun. 226:362-368.
3. Chatterjee, A., D. Saranath, P. Bhatter, and N. Mistry. 2013. Global transcriptional profiling of longitudinal clinical isolates of Mycobacterium tuberculosis exhibiting rapid accumulation of drug resistance. PLoS One 8:e54717.
4. Colangeli R., D. Helb, S. Sridharan, J. Sun, M. Varma-Basil, MH. Hazbón, R. Harbacheuski, N.J. Megjugorac, W.R. Acobs, Jr., A. Holzenburg, J.C. Sacchettini, and D. Alland. 2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Mol. Microbiol. 55:1829-1840.
5. Committee of Chinese anti-Tuberculosis Association. 2006. Chinese Anti-Tuberculosis Association Protocols for tuberculosis diagnosis in laboratory. 1st. Beijing: Chinese Educational and Cultural Publisher.
6. De Rossi, E., J.A. Ainsa, and G. Riccardi. 2006. Role of mycobacterial efflux transporters in drug resistance: an unresolved question. FEMS Microbiol. Rev. 30:36-52.
7. De Rossi, E., P. Arrigo, M. Bellinzoni, P.A. Silva, C. Martn, J.A. Ánsa, P. Guglierame, and G. Riccardi. 2002. The multidrug transporters belonging to major facilitator superfamily in Mycobacterium tuberculosis. Mol. Med. 8:714-724.
8. Escribano, I., J.C. Rodŕguez, B. Llorca, E. Garcá-Pachon, M. Ruiz, and G. Royo. 2007. Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. Chemotherapy 53:397-401.
9. Fattorini, L., E. Iona, M.L. Ricci, O.F. Thoresen, G. Orrù , M.R. Oggioni, E. Tortoli, C. Piersimoni, P. Chiaradonna, M. Tronci, G. Pozzi, and G. Orefici. 1999. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb. Drug Resist. 5:265-270.
10. Gupta, A.K., D.S. Chauhan, K. Srivastava, R. Das, S. Batra, M. Mittal, P. Goswami, N. Singhal, V.D. Sharma, K. Venkatesan, S.E. Hasnain, and V.M. Katoch. 2006. Estimation of efflux mediated multi-drug resistance and its correlation with expression levels of two major efflux pumps in mycobacteria. J. Commun. Dis. 38:246-254.
11. Gupta, S., S. Tyagi, D.V. Almeida, M.C. Maiga, N.C. Ammerman, and W.R. Bishai. 2013. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am. J. Respir. Crit. Care Med. 188: 600-607.
12. Hatfull, G.F., and W.R. Jacobs, Jr. 2000. Molecular Genetics of Mycobacteria. Washington DC: ASM Press, pp. 235-256.
13. Helal, Z.H., M.S. Ashour, S.A. Eissa, G. Abd-Elatef, T. Zozio, S. Babapoor, N. Rastogi, and M.I. Khan. 2009. Unexpectedly high proportion of ancestral Manu genotype Mycobacterium tuberculosis strains cultured from tuberculosis patients in Egypt. J. Clin. Microbiol. 47:2794-2801.
14. Kamerbeek, J., L. Schouls, A. Kolk, M. van Agterveld, D. van Soolingen, S. Kuijper, A. Bunschoten, H. Molhuizen, R. Shaw, M. Goyal, and J. van Embden. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35:907-914.
15. Li, X.Z., L. Zhang, and H. Nikaido. 2004. Efflux pumpmediated intrinsic drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:2415-2423.
16. Long, Q., W. Li, Q. Du, Y. Fu, Q. Liang, H. Huang, and J. Xie. 2012. gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China. Int. J. Antimicrob. Agents. 39:486-489.
17. Louw, G.E., R.M. Warren, N.C. van Pittius, R. Leon, A. Jimenez, R. Hernandez-Pando, C.R. McEvoy, M. Grobbelaar, M. Murray, P.D. van Helden, and T.C. Victor. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184:269-276.
18. Machado, D., I. Couto, J. Perdigaõ, L. Rodrigues, I. Portugal, P. Baptista, B. Veigas, L. Amaral, and M. Viveiros. 2012. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS One 7:e34538.
19. Malik, S., M. Willby, D. Sikes, O.V. Tsodikov, and J.E. Posey. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754.
20. Martin, A., M. Camacho, F. Portaels, and J.C. Palomino. 2003. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple and inexpensive method. Antimicrob. Agents Chemother. 47:3616-3619.
21. Mukherjee, J.S., M.L. Rich, A.R. Socci, J.K. Joseph, F.A. Virú , S.S. Shin, J.J. Furin, M.C. Becerra, D.J. Barry, J.Y. Kim, J. Bayona, P. Farmer, M.C. Smith Fawzi, and K.J. Seung. 2004. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet. 363:474-481.
22. Nebenzahl-Guimaraes, H., K.R. Jacobson, M.R. Farhat, and M.B. Murray. 2013. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 69:331-342.
23. Pasca, M.R., P. Guglierame, F. Arcesi, M. Bellinzoni, E. De Rossi, and G. Riccardi. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:3175-3178.
24. Pillay, M., and A.W. Sturm. 2007. Evolution of the extensively drug-resistant F15/LAM4/KZN strain of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. Clin. Infect. Dis. 45:1409-1414.
25. Ryan, B.M., T.J. Dougherty, D. Beaulieu, J. Chuang, B.A. Dougherty, and J.F. Barrett. 2001. Efflux in bacteria: what do we really know about it Expert Opin. Investig. Drugs 10:1409-1422.
26. Schmalstieg, A.M., S. Srivastava, S. Belkaya, D. Deshpande, C. Meek, R. Leff, N.S. van Oers, and T. Gumbo. 2012. The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob. Agents Chemother. 56:4806-4815.
27. Singh, M., G.P. Jadaun, Ramdas, K. Srivastava, V. Chauhan, R. Mishra, K. Gupta, S. Nair, D.S. Chauhan, V.D. Sharma, K. Venkatesan, and V.M. Katoch. 2011. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J. Med. Res. 133:535-540.
28. Singh, R., M.C. Swick, K.R. Ledesma, Z. Yang, M. Hu, L. Zechiedrich, and V.H. Tam. 2012. Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli. Antimicrob. Agents. Chemother. 56:1680-1685.
29. Sulochana S, S. Narayanan, C.N. Paramasivan, C. Suganthi, and P.R. Narayanan. 2007. Analysis of fluoroqunolone resistance in clinical isolates of Mycobacterium tuberculosis from India. J. Chemother. 19:89-93.
30. Sun, Z., J. Zhang, H. Song, X. Zhang, Y. Li, M. Tian, Y. Liu, Y. Zhao, and C. Li. 2010. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates. Int. J. Tuberc. Lung Dis. 14:1436-1441.
31. Sun, Z., J. Zhang, X. Zhang, S. Wang, Y. Zhang, and C. Li. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 31:115-121.
32. Tao, J., J. Han, H. Wu., X. Hu., J. Deng., J. Fleming., A. Maxwell, L. Bi, and K. Mi. 2013. Mycobacterium fluoroquinolone resistance protein B, a novel small GTPase, is involved in the regulation of DNA gyrase and drug resistance. Nucleic Acids Res. 41:2370-2381.
33. [WHO] World Health Organization 2008. World Health Organization. 2008. Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva, WHO, 2008 (WHO/HTM/TB/2008.392) Available at www.who.int/tb/publications/2008/who-htm-tb-2008-392.pdf. (Accessed 25 February 2012).
34. [WHO] The World Health Organization. 2013. Global Tuberculosis Report 2012. Available at http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502-eng.pdf. (Accessed 28 March 2013).
35. Xu, C., B.N. Kreiswirth, S. Sreevatsan, J.M. Musser, and K. Drlica. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis. 174:1127-1130.